Retatrutide
$110.00
Retatrutide is an investigational (experimental) once-weekly injectable medication developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and metabolic disorders. It is a triple hormone receptor agonist, targeting:
GLP-1 (glucagon-like peptide-1) – reduces appetite and improves insulin secretion
GIP (glucose-dependent insulinotropic polypeptide) – supports insulin release and fat metabolism
Glucagon receptors – increases energy expenditure and fat breakdown
Key Features:
Mechanism: Combines the effects of GLP-1, GIP, and glucagon receptor activation
Benefits (in clinical trials):
Substantial weight loss (up to or exceeding 24% in some studies)
Improved blood sugar control
Potential benefits for fatty liver disease and metabolic syndrome
Dosing: Administered once weekly via subcutaneous injection
Status: Still in clinical trials (as of mid-2025), not yet FDA-approved
Common Side Effects (based on trials):
Nausea, vomiting, diarrhea, constipation
Decreased appetite
Potential gastrointestinal discomfort, especially during dose escalation
Summary:
Retatrutide is a next-generation weight loss and diabetes treatment in development, showing promising results in early studies by targeting three metabolic hormone pathways for more powerful effects than current GLP-1 medications like Mounjaro or Wegovy. Approval is pending further clinical trial outcomes.
